INVX Stock Analysis: Innovex International | NYSE
Oil & Gas Equipment & Services | NYSE, USA | Market Cap: 1.679m USD | 12M Return: 56.8% | Charts, Fundamentals & Technical Analysis
Avg Turnover: 10.3M
Qual. Beats: 0
Rev. Trend: 98.3%
Qual. Beats: 0
Warnings
Tailwinds
No distinct edge detected
Seasonality 10.5 years of data
How good or bad each month usually is (without trend). The score below shows how much you can trust it: 0 = pure chance, >40 gets interesting and >55 is strong.
Innovex International, Inc. (NYSE: INVX) is a U.S.-based oilfield services company that designs, manufactures, sells, and rents mission-critical engineered products for the global oil and natural gas industry. Its product portfolio spans the full well lifecycle, covering drilling enhancement tools, fishing and intervention equipment, well production and artificial lift solutions, subsea wellhead systems, well completion products (including liner hangers, frac plugs, and packers), well construction tools, and cementing support products. The company serves international and national oil companies, independent exploration and production firms, and multinational service companies, with applications across both onshore and offshore wells.
Founded in 2016 and headquartered in Humble, Texas, Innovex operates as a small-cap energy company within the GICS Oil & Gas Drilling sub-industry. The oilfield services sector in which it competes is closely tied to upstream capital spending and commodity prices, with revenue typically generated through a mix of product sales and equipment rentals that recur across drilling and completion campaigns.
- Crude oil price recovery boosts E&P capital spending
- North American rig count growth drives drilling tool demand
- Deepwater project awards expand subsea wellhead backlog
| Net Income: 51.9m TTM > 0 and > 6% of Revenue |
| FCF/TA: 0.11 > 0.02 and ΔFCF/TA 3.49 > 1.0 |
| NWC/Revenue: 61.95% < 20% (prev 62.96%; Δ -1.01% < -1%) |
| CFO/TA 0.14 > 3% & CFO 179.7m > Net Income 51.9m |
| Net Debt (-124.5m) to EBITDA (157.3m): -0.79 < 3 |
| Current Ratio: 5.10 > 1.5 & < 3 |
| Outstanding Shares: last quarter (68.9m) vs 12m ago -0.77% < -2% |
| Gross Margin: 27.05% > 18% (prev 33.63%; Δ -6.58% > 0.5%) |
| Asset Turnover: 78.66% > 50% (prev 64.65%; Δ 14.01% > 0%) |
| Interest Coverage Ratio: 38.35 > 6 (EBIT TTM 87.1m / Interest Expense TTM 2.27m) |
| A: 0.47 (Total Current Assets 752.9m - Total Current Liabilities 147.8m) / Total Assets 1.29b |
| B: 0.20 (Retained Earnings 254.5m / Total Assets 1.29b) |
| C: 0.07 (EBIT TTM 87.1m / Avg Total Assets 1.24b) |
| D: 4.01 (Book Value of Equity 1.03b / Total Liabilities 256.8m) |
| Altman-Z'' = 8.41 = AAA |
| DSRI: 0.72 (Receivables 245.6m/269.1m, Revenue 976.9m/773.2m) |
| GMI: 1.24 (GM 33.63% / 27.05%) |
| AQI: 0.94 (AQ_t 0.25 / AQ_t-1 0.27) |
| SGI: 1.26 (Revenue 976.9m / 773.2m) |
| TATA: -0.10 (NI 51.9m - CFO 179.7m) / TA 1.29b) |
| Beneish M = -2.89 (Cap -4..+1) = A |
As of July 14, 2026, the stock is trading at USD 25.50 with a total of 228,413 shares traded. Over the past week, the price has changed by +5.73%, over one month by -13.51%, over three months by -3.41% and over the past year by +56.83%.
Current recommended Stop Loss: 23.10 (which is 9.4% or 2.2 ATR below the current price).
Innovex International has received a consensus analysts rating of 2.00. Therefore, it is recommended to sell INVX.
- StrongBuy: 0
- Buy: 0
- Hold: 0
- Sell: 1
- StrongSell: 0
| Analysts Target Price | 33 | 29.4% |
P/E Trailing = 31.6447
P/S = 1.7189
P/B = 1.6316
Revenue TTM = 976.9m USD
EBIT TTM = 87.1m USD
EBITDA TTM = 157.3m USD
Long Term Debt = 57.4m USD (estimated: total debt 76.2m - short term 18.8m)
Short Term Debt = 18.8m USD (from shortTermDebt, last quarter)
Debt = 76.2m USD (from shortLongTermDebtTotal, last quarter) (leases 76.2m already included)
Net Debt = -124.5m USD (calculated: Debt 76.2m - CCE 200.7m)
Enterprise Value = 1.55b USD (1.68b + Debt 76.2m - CCE 200.7m)
Interest Coverage Ratio = 38.35 (Ebit TTM 87.1m / Interest Expense TTM 2.27m)
EV/FCF = 10.67x (Enterprise Value 1.55b / FCF TTM 145.8m)
FCF Yield = 9.38% (FCF TTM 145.8m / Enterprise Value 1.55b)
FCF Margin = 14.92% (FCF TTM 145.8m / Revenue TTM 976.9m)
Net Margin = 5.31% (Net Income TTM 51.9m / Revenue TTM 976.9m)
Gross Margin = 27.05% ((Revenue TTM 976.9m - Cost of Revenue TTM 712.6m) / Revenue TTM)
Gross Margin QoQ = 28.57% (prev 23.26%)
Tobins Q-Ratio = 1.21 (Enterprise Value 1.55b / Total Assets 1.29b)
Interest Expense / Debt = 2.98% (Interest Expense 2.27m / Debt 76.2m)
Taxrate = 39.38% (33.7m / 85.6m)
NOPAT = 52.8m (EBIT 87.1m * (1 - 39.38%))
Current Ratio = 5.10 (Total Current Assets 752.9m / Total Current Liabilities 147.8m)
Debt / Equity = 0.07 (Debt 76.2m / totalStockholderEquity, last quarter 1.03b)
Debt / EBITDA = -0.79 (Net Debt -124.5m / EBITDA 157.3m)
Debt / FCF = -0.85 (Net Debt -124.5m / FCF TTM 145.8m)
Total Stockholder Equity = 1.03b (last 4 quarters mean from totalStockholderEquity)
RoA = 4.18% (Net Income 51.9m / Total Assets 1.29b)
RoE = 5.03% (Net Income TTM 51.9m / Total Stockholder Equity 1.03b)
RoCE = 8.00% (EBIT 87.1m / Capital Employed (Equity 1.03b + L.T.Debt 57.4m))
RoIC = 4.76% (NOPAT 52.8m / Invested Capital 1.11b)
WACC = 8.14% (E(1.68b)/V(1.76b) * Re(8.43%) + D(76.2m)/V(1.76b) * Rd(2.98%) * (1-Tc(0.39)))
Discount Rate = 8.43% (= CAPM, Blume Beta Adj.)
Shares (quarterly) Correlation: 58.43 | Cagr: 14.77%
[DCF] Terminal Value 77.97% ; FCFF base≈124.9m ; Y1≈143.2m ; Y5≈210.8m
[DCF] Fair Price = 47.21 (EV 3.17b - Net Debt -124.5m = Equity 3.30b / Shares 69.8m; r=8.35% [WACC [floored]]; 5y FCF grow 15.0% → 2.50% )
EPS Correlation: N/A | EPS CAGR: N/A | SUE: 0.30 | # QB: 0
Revenue Correlation: 98.25 | Revenue CAGR: 44.58% | SUE: 0.12 | # QB: 0
EPS current Quarter (2026-06-30): EPS=0.30 | Chg30d=+0.00% | Revisions=+0% | Analysts=3
EPS next Quarter (2026-09-30): EPS=0.36 | Chg30d=+0.00% | Revisions=-40% | Analysts=3
EPS current Year (2026-12-31): EPS=1.42 | Chg30d=+5.71% | Revisions=+0% | GrowthEPS=+34.5% | GrowthRev=+2.8%
EPS next Year (2027-12-31): EPS=1.95 | Chg30d=+4.79% | Revisions=+0% | GrowthEPS=+37.5% | GrowthRev=+9.4%
[Analyst] Revisions Ratio: -29% (up=1, down=3)